Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $6500.0.

  • Theravance Biopharma's Other Working Capital Changes fell 9820.44% to $6500.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6500.0, marking a year-over-year decrease of 9820.44%. This contributed to the annual value of -$7.4 million for FY2024, which is 19803.9% down from last year.
  • Per Theravance Biopharma's latest filing, its Other Working Capital Changes stood at $6500.0 for Q3 2025, which was down 9820.44% from $50500.0 recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Other Working Capital Changes peaked at $10.9 million during Q4 2023, and registered a low of -$4.0 million during Q1 2024.
  • Moreover, its 5-year median value for Other Working Capital Changes was -$1.4 million (2023), whereas its average is -$442631.6.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first soared by 42724.62% in 2023, then tumbled by 18793.72% in 2024.
  • Theravance Biopharma's Other Working Capital Changes (Quarter) stood at -$2.8 million in 2021, then skyrocketed by 173.14% to $2.1 million in 2022, then surged by 427.25% to $10.9 million in 2023, then plummeted by 129.67% to -$3.2 million in 2024, then soared by 100.2% to $6500.0 in 2025.
  • Its Other Working Capital Changes was $6500.0 in Q3 2025, compared to $50500.0 in Q2 2025 and -$1.7 million in Q1 2025.